Cantor Fitzgerald Reiterates Their Hold Rating on Amag Pharmaceuticals

By Ryan Adsit

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Hold rating on Amag Pharmaceuticals (NASDAQ: AMAG), with a price target of $23. The company’s shares closed on Friday at $18.35, close to its 52-week high of $36.83.

Tanner wrote:

“AMAG disclosed that the Makena auto-injector sNDA has been accepted for review and that the FDA set a PDUFA date of February 14, 2018.”

According to, Tanner is a 4-star analyst with an average return of 12.3% and a 61.7% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.

Amag Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $25.

Based on Amag Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $139 million and GAAP net loss of $36.56 million. In comparison, last year the company earned revenue of $109 million and had a GAAP net loss of $7.53 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA.